TIM-1-Fc Fusion Protein Regulates Th1/Th2 and Th17/Treg Immune Imbalance in Mice with Asthma
曹津萌 1卿吉琳 2朱莉雅 3魏燕 3赵艺莲 4叶超 1陈治中5
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 桂林医学院临床医学院,桂林 541199
2. 广西壮族自治区人民医院生殖医学中心,南宁 530021
3. 广西中医药大学研究生院,南宁 530200
4. 广西医科大学第一临床医学院,南宁 530021
5. 广西壮族自治区人民医院精准联合检验中心,南宁 530021
折叠
摘要
目的 制备T细胞免疫球蛋白和黏蛋白结构域1(T cell immunoglobulin domain and mucin domain protein-1,TIM-1)-Fc融合蛋白并探讨TIM-1-Fc融合蛋白对卵白蛋白(ovabumin,OVA)诱导的哮喘小鼠的干预作用及潜在作用机制.方法 通过基因工程技术获得TIM-1-Fc融合蛋白.采用腹腔注射OVA氢氧化铝溶液致敏建立过敏性哮喘小鼠模型,随机分为对照组、哮喘组和TIM-1-Fc干预组.每次干预前20 min,使用40 μL卵白蛋白生理盐水溶液(OVA-NS)滴鼻,TIM-1-Fc融合蛋白干预包括TIM-1-Fc滴鼻组(每只小鼠每次给予1 μg/40μLTIM-1-Fc滴鼻)和TIM-1-Fc注射组(每只小鼠每次给予6μg/200μLTIM-1-Fc腹腔注射),每天1次,连续7 d,对照组用生理盐水替代.采用苏木精-伊红(HE)染色观察肺组织病理变化;采用流式细胞术检测小鼠外周血中辅助性T细胞2(type 2 T helper cells,Th2)、辅助性T细胞17(type 17 T helper cells,Th17)和调节性T细胞(Treg)比例及相关细胞因子水平.结果 成功构建TIM-1-Fc融合蛋白,成功构建OVA诱导的过敏性哮喘小鼠模型.与哮喘组相比,TIM-1-Fc融合蛋白干预后显著减轻了哮喘小鼠气道炎性损伤和肺组织损伤;TIM-1-Fc融合蛋白干预能显著降低外周血中TIM-1+CD4+T细胞和TIM-1+Th17细胞比例,使TIM-1 Treg细胞增多,显著降低Th2、Th17细胞比例,提高Treg细胞比例,调节哮喘中Th1/Th2和Th17/Treg免疫失衡.结论 TIM-1-Fc融合蛋白改善OVA诱导的过敏性哮喘小鼠气道炎症和肺组织损伤,其作用机制可能与TIM-1-Fc融合蛋白对Th1/Th2和Th17/Treg的免疫调节有关.
Abstract
Objective To prepare T cell immunoglobulin domain and mucin domain 1 protein-1(TIM-1)-Fc fusion protein,and to investigate the intervention effect of TIM-1-FC fusion protein on ovabumin(OVA)-induced asthma mice as well as its po-tential mechanism.Methods Through genetic engineering,pcDNA3.1(+)-TIM-1-Fc plasmid was constructed and stably transfected into CHO cells.Cell culture supernatant was collected and purified,and TIM-1-Fc fusion protein was ob-tained.Mouse model of allergic asthma was established by intraperitoneal injection of OVA aluminum hydroxide solution.The mice were randomly divided into control group,asthma group and TIM-1-Fc intervention group.The TIM-1-Fc intervention group included TIM-1-Fc nasal drop group and TIM-1-Fc injection group.20 min before each intervention,40 μL ovalbumin sa-line solution(OVA-NS)was used for nasal drops.Protein TIM-1-Fc nasal drops group(1 μg/40 μL TIM-1-Fc nasal drops was administrated in each mouse)and TIM-1-Fc injection group(6 μg/200 μL TIM-1-Fc was injected intraperitoneally in each mouse)were interfered with TIM-1-Fc fusion,once a day for 7 days.Normal saline was used as replacement in the control group.Hematoxylin-eosin staining(HE)was used to observe the pathological changes of lung tissue.Flow cytometry was used to detect the proportion of type 2 helper T cells(Th2),type 17 helper T cells(Th17),regulatory T cells(Treg)and the levels of related cytokines in peripheral blood of mice.Results TIM-1-Fc fusion protein and OVA-induced allergic asthma mouse model was successfully constructed.Compared with asthma group,TIM-1-Fc fusion protein could significantly reduce airway inflam-matory injury and lung tissue injury in asthmatic mice.TIM-1-Fc fusion protein intervention could significantly reduce the pro-portion of TIM-1 CD4+T cells and TIM-1+Th17 cells in peripheral blood,increase the number of TIM-1+Treg cells,signifi-cantly reduce the proportion of Th2 and Th17 cells,and increase the proportion of Treg cells.It could modulate Th1/Th2 and Th17/Treg immune imbalances in asthma.Conclusion TIM-1-Fc fusion protein improves airway inflammation and lung tissue injury in OVA-induced allergic asthma mice,and its mechanism may be related to the immune regulation of Th1/Th2 and Th17/Treg by TIM-1-Fc fusion protein.
维普
万方数据